Slideshow

Treating Primary and Secondary Raynaud’s

In this slideshow, we summarize the difference between primary and secondary Raynaud’s phenomenon and recommended treatments.

Raynaud’s phenomenon affects up to five percent of the general population, but for 37 percent of people with the disorder, it leads to connective tissue disease. In this slideshow, we sum up identifying factors for primary Raynaud’s and secondary Raynaud’s as described by Fredrick M. Wigley, M.D., and Nicholas A. Flavahan, Ph.D., two Johns Hopkins University School of Medicine physicians who, on August 11, published a related review article in the New England Journal of Medicine. 

References:

Fredrick M. Wigley, M.D., and Nicholas A. Flavahan, Ph.D. "Raynaud’s Phenomenon," N Engl J Med 2016; 375:556-565August 11, 2016DOI: 10.1056/NEJMra1507638

Related Videos
The Evolving Use of Biologics for PsA Care, with Philip Mease, MD
Achieving Complete Renal Response and Reducing Corticosteroid Use in Lupus Nephritis Treatment With Obinutuzmab, with Richard Furie, MD
Identifying B-cell Depleting Agents for Lupus Nephritis, with Richard Furie, MD
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
© 2025 MJH Life Sciences

All rights reserved.